WALL STREET: GENENTECH TO LEAD LUNG CANCER MARKET (AP)

Genentech Inc. ’s drug Avastin will expected sojourn widespread in a lung cancer marketplace over opposition ImClone Systems Inc. ’s Erbitux, multiform analysts pronounced Monday following a recover of clinical interpretation during a American Society of Clinical Oncology’s annual assembly in Chicago.

Tags: , , , , , , ,

Related posts

Leave a Comment

Please note: Comment moderation is enabled and may delay your comment. There is no need to resubmit your comment.